These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7821925)

  • 1. Antigenic variation of primate lentiviruses in humans and experimentally infected macaques.
    Fenyö EM
    Immunol Rev; 1994 Aug; 140():131-46. PubMed ID: 7821925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections.
    Fenyö EM; Putkonen P
    Immunol Lett; 1996 Jun; 51(1-2):95-9. PubMed ID: 8811351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.
    Scarlatti G; Albert J; Rossi P; Hodara V; Biraghi P; Muggiasca L; Fenyö EM
    J Infect Dis; 1993 Jul; 168(1):207-10. PubMed ID: 8515110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amniotic fluid has higher relative levels of lentivirus-specific antibodies than plasma and can contain neutralizing antibodies.
    Jaspan HB; Robinson JE; Amedee AM; Van Dyke RB; Garry RF
    J Clin Virol; 2004 Nov; 31(3):190-7. PubMed ID: 15465411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIV
    Jia M; Lu H; Kong XP; Cheng-Mayer C; Wu X
    Viruses; 2018 May; 10(5):. PubMed ID: 29772652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of a primary isolate-like virus from simian and human immunodeficiency virus-infected macaque having broad neutralizing activity.
    Miyazaki Y; Kuwata T; Takehisa J; Hayami M
    AIDS Res Hum Retroviruses; 2002 Apr; 18(6):469-75. PubMed ID: 11958690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin.
    Rasmussen RA; Montefiori DC; Robinson HL; McClure HM; Ruprecht RM
    J Infect Dis; 2001 Dec; 184(12):1603-7. PubMed ID: 11740737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
    J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1.
    Scarlatti G; Leitner T; Hodara V; Halapi E; Rossi P; Albert J; Fenyö EM
    AIDS; 1993 Nov; 7 Suppl 2():S45-8. PubMed ID: 8161445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys.
    Amos JD; Himes JE; Armand L; Gurley TC; Martinez DR; Colvin L; Beck K; Overman RG; Liao HX; Moody MA; Permar SR
    J Virol; 2015 Sep; 89(18):9485-98. PubMed ID: 26157116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies.
    Ferrantelli F; Rasmussen RA; Buckley KA; Li PL; Wang T; Montefiori DC; Katinger H; Stiegler G; Anderson DC; McClure HM; Ruprecht RM
    J Infect Dis; 2004 Jun; 189(12):2167-73. PubMed ID: 15181562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic and biological alteration of a human immunodeficiency virus type 1 (HIV-1)-simian immunodeficiency virus strain mac chimera, with HIV-1 Env, recovered from a long-term carrier monkey.
    Igarashi T; Kuwata T; Takehisa J; Ibuki K; Shibata R; Mukai R; Komatsu T; Adachi A; Ido E; Hayami M
    J Gen Virol; 1996 Aug; 77 ( Pt 8)():1649-58. PubMed ID: 8760411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence.
    Burns DP; Desrosiers RC
    Curr Top Microbiol Immunol; 1994; 188():185-219. PubMed ID: 7523031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
    J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
    Baba TW; Liska V; Hofmann-Lehmann R; Vlasak J; Xu W; Ayehunie S; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Lu Y; Wright JE; Chou TC; Ruprecht RM
    Nat Med; 2000 Feb; 6(2):200-6. PubMed ID: 10655110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
    Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
    J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction.
    Brocca-Cofano E; Kuhrt D; Siewe B; Xu C; Haret-Richter GS; Craigo J; Labranche C; Montefiori DC; Landay A; Apetrei C; Pandrea I
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.